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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Colombian Spanish 
language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, and construct validity (convergent and 
discriminant validity). A total of 22 JIA patients (9.1% systemic, 27.3% RF-negative polyarthritis, 36.4% enthesitis-related 
arthritis, 27.2% other categories) were enrolled in the paediatric centre of Bogota. All JAMAR components revealed good 
psychometric performances. In conclusion, the Colombian Spanish version of the JAMAR is a valid tool for the assessment 
of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Colombian Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
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parent/patient-reported outcomes in JIA, including overall 
well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Colombian Spanish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from October 2012 
to August 2017. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-culturally adapted 
in a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
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equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Test–retest reliability of the Colombian Span-
ish version of the JAMAR was not assessed.
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Colombian Spanish parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Colombian Spanish JAMAR was fully cross-culturally 
adapted from the Castilian Spanish version.
All 123 lines of the parent version of the JAMAR were 
understood by at least 80% of the ten parents tested (median 
100%; range 90–100%). All the 120 lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 90–100%). Both versions of 
the JAMAR were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 22 JIA patients were enrolled at the paediatric 
rheumatology centre of Bogota.
In the 22 JIA subjects, the JIA categories were 9.1% with 
systemic arthritis, 13.6% with oligoarthritis, 27.3% with RF-
negative polyarthritis, 13.6% with RF-positive polyarthritis 
and 36.4% with enthesitis-related arthritis. Notably, none of 
the enrolled JIA patients is affected with psoriatic arthritis 
or with undifferentiated arthritis (Table 1).
All the 22 subjects had the parent version of the JAMAR 
completed by a parent. The JAMAR was completed by 15/22 
(68.2%) mothers and 7/22 (31.8%) fathers. The child version 
of the JAMAR was completed by 20/22 (90.9%) children 
age 10.7 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (1st–3rd quartile)] obtained for the PF, the 
PhH, the PsH subscales and total score of the HRQoL scales. 
At the study units, it was not possible to recruit healthy chil-
dren. Therefore, in this dataset, it was not possible, to assess 
the efficacy of the tools in discriminating between health 
subjects and affected children.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. A 
reduced number of response choices was used for all the 
different HRQoL items (with the exception of item 3), and 
for all the PF items.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 0% (0–0%) for the PF and 1% (1–1%) for 
the HRQoL.
Floor and ceiling effect
The median floor effect was 86.4% (81.8–90.9%) for the PF 
items, 77.3% (63.6–81.8%) for the HRQoL PhH items, and 
63.6% (59.1–63.6%) for the HRQoL PsH items. The median 
ceiling effect was 0% (0–0%) for the PF items, 0% (0–0%) 
for the HRQoL PhH items, and 0% (0–0%) for the HRQoL 
PsH items. The median floor effect was 36.4% for the pain 
VAS, 50.0% for the disease activity VAS and 36.4% for the 
well-being VAS. The median ceiling effect was 0% for the 
pain VAS, 0% for the disease activity VAS and 0% for the 
well-being VAS.
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Equal items–scale correlations (second Likert 
assumption)
Pearson’s items–scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 100% 
of the PF items, and 15 and for 80% of the HRQoL items, 
with the exception of items 1 and 2.
Table 1  Descriptive statistics (medians, 1st and 3rd quartiles or absolute frequencies and %) for the 22 JIA patients
Data related to the JAMAR refers to the 22 JIA patients for whom the questionnaire has been completed by the parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS Visual Ana-
logue Scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function 
(total score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges 
from 0 to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic (N = 2) Oligoarthritis 
(N = 3)
RF − polyarthritis 
(N = 6)
RF + Polyarthritis 
(N = 3)
Enthesitis-related 
arthritis (N = 8)
All JIA patients 
(N = 22)
Female 0 (0%) 2 (66.7%) 3 (50%) 3 (100%) 4 (50%) 12 (54.5%)
Age at visit 11 (6.1–16) 14.6 (4.3–16.1) 12.8 (11.2–14.5) 13.5 (11.5–17.9) 16.8 (14.8–17.3) 14.5 (11.5–16.7)
Age at onset 10.4 (5.8–15.1) 10.2 (2.8–11.3) 10.7 (9.4–11.5) 12.7 (7.7–15.8) 13.1 (10.3–14.5) 11.4 (9.4–14.3)
Disease duration 0.6 (0.3–0.9) 4.4 (1.5–4.8) 2.7 (1.9–4.6) 2.2 (0.8–3.9) 3.1 (1.8–4.9) 2.7 (1.4–4.4)
ESR 2 (2–2) 5 (4–17) 11 (4–23) 22 (6–28) 5 (2–8) 6 (4–16)
MD VAS (0–10 cm) 0 (0–0) 0 (0–0) 3 (0–4) 2 (0–4) 0 (0–2) 0 (0–2)
No. of swollen joints 0 (0–0) 0 (0–0) 1.5 (0–5) 0 (0–4) 0 (0–0) 0 (0–0)*
No. of joints with 
pain
0 (0–0) 0 (0–0) 3 (0–6) 0 (0–4) 1 (0–2) 0 (0–2)
No. of joints with 
LOM
0 (0–0) 0 (0–0) 6.5 (0–12) 1 (0–8) 0 (0–0) 0 (0–2)
No. of active joints 0 (0–0) 0 (0–0) 1.5 (0–5) 0 (0–4) 0 (0–0) 0 (0–0)*
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Uveitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PF total score 0 (0–0) 0 (0–3) 5 (4–5) 4 (0–11) 0 (0–0) 0 (0–5)
Pain VAS 0 (0–0) 1 (0–2) 2 (0–5) 1 (1–1) 0 (0–0) 0 (0–2)
Disease activity 
VAS
0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0) 0 (0–1)
Well-being VAS 0 (0–0) 0 (0–1) 0.5 (0–2) 1.5 (0–4) 0 (0–3)
HRQoL-PhH 49.5 (0–99) 1 (0–3) 1.5 (0–2) 1 (1–2) 1 (0–3) 1 (0–3)
HRQo-PsH 51 (3–99) 0 (0–1) 1 (0–3) 2 (1–8) 2 (0–3.5) 1.5 (0–3)
HRQoL total score 51.5 (4–99) 2 (0–3) 3 (0–4) 4 (2–9) 4 (0–6.5) 3 (0–6)
Pain/swell. in > 1 
joint
0 (0%) 0 (0%) 5 (83.3%) 2 (66.7%) 4 (50%) 11 (50%)
Morning stiff-
ness > 15 min
0 (0%) 0 (0%) 1 (16.7%) 0 (0%) 1 (12.5%) 2 (9.1%)
Subjective remission 1 (50%) 0 (0%) 4 (66.7%) 2 (66.7%) 4 (50%) 11 (50%)
In treatment 2 (100%) 1 (33.3%) 6 (100%) 3 (100%) 8 (100%) 20 (90.9%)
Reporting side 
effects
0 (0%) 0 (0%) 0 (0%) 1 (33.3%) 2 (25%) 3 (15%)
Taking medication 
regularly
2 (100%) 1 (100%) 5 (83.3%) 3 (100%) 8 (100%) 19 (95%)
With problems 
attending school
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Satisfied with dis-
ease outcome
1 (50%) 3 (100%) 2 (33.3%) 3 (100%) 6 (75%) 15 (68.2%)
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Items internal consistency (third Likert assumption)
Pearson’s items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 80% of items of the HRQoL (except for 
items 1 and 2).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.88 for PF-LL, 0.85 for PF-HW, 0.90 
for PF-US. Cronbach’s alpha was 0.51 for HRQoL-PhH and 
0.77 for HRQoL-PsH.
Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of the HRQoL items 4 and 5 (data not shown).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.3 to 
0.6 (median 0.4). The PF total score best correlation was 
observed with the parent’s assessment of pain (r = 0.61, 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 22/22) Child (N = 20/22)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 86.4% 85.0%
 HRQoL PhH 77.3% 60.0%
 HRQoL PsH 63.6% 45.0%
 Pain VAS 36.4% 20.0%
 Disease activity VAS 50.0% 25.0%
 Well-being VAS 36.4% 30.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 0.0% 0.0%
 HRQoL-PsH 0.0% 5.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 100% for PF, 80% for HRQoL 87% for PF, 80% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 80% for HRQoL 53% for PF,90% for HRQoL
Cronbach’s alpha
 PF-LL 0.88 0.87
 PF-HW 0.85 0.53
 PF-US 0.90 0.48
 HRQoL-PhH 0.51 0.81
 HRQoL-PsH 0.77 0.63
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 80% for HRQoL 93% for PF, 100% for HRQoL
Spearman’s correlation with JIA core set variables, median
 PF 0.4 0.2
 HRQoL PhH 0.4 0.2
 HRQoL PsH 0.2 0.1
 Pain VAS 0.3 0.3
 Disease activity VAS − 0.1 -0.1
 Well-being VAS 0.3 0.3
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p = 0.03). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from − 0.05 to 0.7 (median 0.4), whereas for the PsH 
ranged from − 0.1 to 0.6 (median 0.2). The PhH showed 
the best correlation with the parent’s assessment of pain 
(r = 0.98, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.7, p = 0.007). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred 
and laboratory measures were 0.3 (0.2–0.4), − 0.1 (− 0.1 
to 0.2), 0.3 (0.1–0.3), respectively.
Discussion
In this study, the Colombian Spanish version of the 
JAMAR was cross-culturally adapted from the Castilian 
Spanish version. According to the results of the valida-
tion analysis, the Colombian Spanish parent and patient 
versions of the JAMAR possess satisfactory psychometric 
properties. However, because it was not possible to recruit 
healthy children, it was not possible to assess the efficacy 
of the tools in discriminating between health subjects and 
affected children.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: two HRQoL items 
(“Difficulty of taking care of him/herself” and “difficulty 
of taking a 15 min walk or walking up a flight of stairs”) 
showed a lower item’s internal consistency. However, the 
overall internal consistency was at least acceptable for all 
the domains, with the exception of the HRQoL-PhH Cron-
bach’s alpha that was poor.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the child version of the JAMAR 
are similar, although slightly poorer, to those obtained for 
the parent version, which suggests that children are equally 
reliable proxy reporters of their disease and health status 
as their parents. Test–retest reliability was not assessed in 
this patient sample. The JAMAR is aimed to evaluate the 
side effects of medications and school attendance, which 
are other dimensions of daily life that were not previously 
considered by other HRQoL tools. This may provide use-
ful information for intervention and follow-up in health 
care. In conclusion, the Colombian Spanish version of 
the JAMAR was found to have satisfactory psychometric 
properties and it is, thus, a reliable and valid tool for the 
multidimensional assessment of children with JIA.
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